Solistaa Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Solistaa Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, g…

2017-11-27 Pondicherry, Pondicherry Active Unlisted Active Compliant
Share
Connect MCP
SP Solistaa Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Solistaa Pharmaceuticals Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
76/100
Trust Score
Low Risk

Solistaa Pharmaceuticals Private Limited is assessed as Low Risk with a Trust Score of 76/100. Solistaa Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 2017, operating in the Food and Beverages sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 27 Jul 2026 from the latest processed filings. Solistaa Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
76/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
81/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
55/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
30/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 30/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Elevated gearing (D/E 1.42).
  • Profitable - internal accruals available.

Charges position: 9 open (31.56 cr) · 10 satisfied (33.75 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others8 48.0 cr
State Bank Of India1 48.0 cr
Sidbi9 48.0 cr
Axis Bank Limited1 48.0 cr
Compliance Score: 81/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • Litigation present in 1 court forum(s).
  • 2 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
PARAMASIVAN SIVARAJAKUMAR 01234567 Director 01/04/2018 6 yrs Approved
KANDOTH KUNNUMPRETH VINUPAL 01234567 Director 01/04/2018 6 yrs Approved
SUNDARARAJALU 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
5 allotment(s) · 3 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 70 · Distress 75
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Operating for 8 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
9 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence78/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment50/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 9 open charge(s) of 31.56 cr already registered.
  • Compliance record supports lending.
Investor view66/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
13 Nov 2024
Charge created
Sidbi - 2.60 cr
30 Sep 2024
Last AGM held
Annual general meeting
07 Jun 2024
Charge satisfied
Sidbi
27 May 2024
Charge satisfied
Others
15 Apr 2024
Charge created
State Bank Of India - 18.75 cr
31 Mar 2024
Share transfer (FY 2024)
8152.00000000 shares to Sivarajakumar Raahulan
Share transfer (FY 2024)
2935.00000000 shares to Sundararajalu
Share transfer (FY 2024)
3913.00000000 shares to Vinupal Kandoth Kunnumpreth
Latest balance sheet
Filed with ROC
26 Mar 2024
Charge created
Sidbi - 1.65 cr
21 Jul 2023
Charge created
Sidbi - 1.20 cr
09 Jan 2023
Charge satisfied
Others
02 Dec 2022
Charge created
Others - 1.10 cr
30 Nov 2022
Charge created
Others - 53.00 Lakh
19 Nov 2022
Charge created
Others - 15.00 cr
10

Key Observations

Auto-generated from the data above
Revenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 5 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Merril Pharma Private Limited U24230GJ2005PTC046638 Ahmedabad, Gujarat, India
Samrvir Biotech Private Limited U24303HR2019PTC082136 Gurgaon, Haryana, India
Gentech Healthcare Private Limited U85110DL2004PTC126874 New Delhi, Delhi, India
Adley Labs U24231PB1992PLC051220 Derabassi, Punjab, India
Evolet Pharmaceuticals Private Limited U24230HR2005PTC127251 Bhorakalan, Haryana, India
Custom Capsules Private Limited U24235MH1988PTC048924 Mumbai, Maharashtra, India
Thinq U24239MH2006PLC165473 Mumbai, Maharashtra, India
Oxford Laboratories U24230MH2000PTC123927 Mumbai, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Solistaa Pharmaceuticals Private Limited before audits and certifications: compliance score 81/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Solistaa Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 30/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 70/100, margin trends, ownership structure and peer set for Solistaa Pharmaceuticals Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 76/100, distress signals and MSME payment-delay disclosures - know whether Solistaa Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Solistaa Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Solistaa Pharmaceuticals Private Limited an active company?

Solistaa Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 81/100 (Low Risk).

Is Solistaa Pharmaceuticals Private Limited financially healthy?

Solistaa Pharmaceuticals Private Limited has a Financial Health Score of 55/100 (Moderate) based on its filed financial statements.

Should I do business with Solistaa Pharmaceuticals Private Limited?

Its overall Trust Score is 76/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Solistaa Pharmaceuticals Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Solistaa Pharmaceuticals Private Limited have loans or charges against its assets?

9 open charge(s) are registered against its assets, and 10 earlier charge(s) stand satisfied.

Is Solistaa Pharmaceuticals Private Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 81/100 (Low Risk).

Is it risky to lend to Solistaa Pharmaceuticals Private Limited?

Its Credit Risk Score is 30/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.